Buscador de Publicaciones

A Gastroenterologist’ clinical experience in COVID 19 and in-hospital mortality and length of stay analysis.
Autores: Valverde-Lopez, F; Tendero-Peinado, C; Lecuona-Munoz, M; Heredia-Carrasco, C; Abellan-Alfocea, P; Ortega-Suazo, EJ; Martin-Rodriguez, MD; Sanchez-Capilla, AD; Sotorrio-Simo, V; Jimenez-Rosales, R; Redondo-Cerezo, E

Real-world outcomes of COVID-19 treatment with remdesivir in a Spanish hospital
Autores: Hidalgo-Tenorio, C; Garcia-Vallecillos, C; Sequera-Arquelladas, S

Medical sequels of COVID-19
Autores: Peramo-Alvarez, FP; Lopez-Zuniga, MA; Lopez-Ruz, MA

Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation
Autores: Salvatierra, J; Aomar-Millan, IF; Hernandez-Quero, J

High-dose corticosteroid pulse therapy increases the survival rate in COVID-19 patients at risk of hyper-inflammatory response
Autores: Zuniga, MAL; Moreno-Moral, A; Ocana-Granados, A; Padilla-Moreno, FA; Castillo-Fernandez, AM; Guillamon-Fernandez, D; Ramirez-Sanchez, C; Sanchez-Palop, M; Martinez-Colmenero, J; Pimentel-Villar, MA; Blazquez-Rosello, S; Moreno-Sanchez, JJ; Lopez-Vilchez,

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study.
Autores: Aomar-Millan, IF; Salvatierra, J; Torres-Parejo, U; Faro-Miguez, N; Callejas-Rubio, JL; Ceballos-Torres, A; Cruces-Moreno, MT; Gomez-Jimenez, FJ; Hernandez-Quero, J; Anguita-Santos, F

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply.-
Autores: Aomar-Millan, IF; Salvatierra, J; Hernandez-Quero, J